As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).  The CDMRP provides execution management support for DHP core research program areas, including the Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP), as the CDMRP Defense Medical Research and Development Program (DMRDP). 

The DMRDP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 DMRDP Program Announcement and General Application Instructions for the following award mechanism is anticipated to be posted on the Grants.gov website in October 2018.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

http://cdmrp.army.mil/pubs/press/2018/18dmrdppreann_jpc6

Multi-Domain Life-Saving Trauma Innovations

Independent investigators at all academic levels (or equivalent)

·        Preproposal is required; application submission is by invitation only.

·        The intent of the “Multi-Domain Life-Saving Trauma Innovations” (MuLTI) effort is to provide cutting-edge medical solutions for the Warfighter.

·        Focus Areas will derive from the following JPC-6/CCCRP portfolios:

○        Battlefield Resuscitation for Immediate Stabilization of Combat Casualties

○                                 Neurotrauma and Traumatic Brain Injury

Prolonged Field Care and En Route Care

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for the award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the DMRDP, JPC-6/CCCRP, or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY18 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (PH/TBIRP) to support critical traumatic brain injury (TBI)- and psychological health (PH)-related research and development efforts to benefit Service members, Veterans, and other beneficiaries of the military health system.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation appropriation.  The U.S. Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP) provides execution management support for DHA research program areas, including the Joint Program Committee-8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP).  The managing agent for this Program Announcement is the CDMRP with strategic oversight from the JPC-8/CRMRP.

The FY18/19 PH/TBIRP will solicit research applications for the following CTRR Focus Areas:

• Mechanisms of Recovery following isolated or cumulative TBI(s) in Service member-relevant injuries:  Clinical research in human subjects that measures physiologic responses to cognitive rehabilitation with the intent to better understand how rehabilitation remediates cognitive or sensorimotor deficits, and ultimately to optimize rehabilitation prescription.

Ecological Assessment:  Investigation of outcome measures focused on military-specific tasks that inform return-to-duty/participation decisions following rehabilitation in patients with TBI. 

Cognitive Rehabilitation:  Evaluation of rehabilitation intervention effectiveness in remediating cognitive impairments and functional limitations after TBI. 

https://www.grants.gov/web/grants/search-grants.html

 

CTRR – Clinical Research Award (CTRR-CRA) – Preproposal due September 24, 2018

Independent investigators at all academic levels (or equivalent)

·        Supports applied and translational research to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI.

·        Supported research can include preclinical studies using human subjects or samples and observational or mechanistic clinical research studies.

·        Clinical trials are not allowed.

·        Preclinical research using animals is not allowed.

·        Must address one or more FY18/19 PH/TBIRP CTRR Focus Areas.

Preproposal is required; application submission is by invitation only.

·       Maximum funding of $2.0M for total costs (includes direct and indirect costs).

• ·       Maximum period of performance is 3 years.
•  
•  

CTRR – Clinical Trial Award (CTRR-CTA) – Preproposal due September 24, 2018

Independent investigators at all academic levels (or equivalent)

·        Supports small, single-site, Phase I clinical trials to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI in Service members, Veterans, and other individuals.

·        Interventions should be limited, existing, and manualized.  Studies may include seeking to optimize dosing in existing interventions.

·        Preclinical studies are not allowed.

·        Must address one or more FY18/19 PH/TBIRP CTRR Focus Areas.

Preproposal is required; application submission is by invitation only.

·       Maximum funding of $2.0M for total costs (includes direct and indirect costs).

• ·       Maximum period of performance is 3 years.

 

CTRR – Clinical Trial Development Award (CTRR-CTDA) – Preproposal due September 24, 2018

Independent investigators at all academic levels (or equivalent)

·       Supports design and development of the necessary research resources that will serve as a foundation for investigator-initiated clinical trials as described above under CTRR – Clinical Trial Award (CTRR-CTA)

·       Final supporting studies required for approval of Investigational New Drug Applications/Investigational Device Exemptions (IND/IDE-enabling) are allowed.  Other preclinical studies are not allowed. 

·       Clinical trials are not allowed within the period of performance of the CTRR-CTDA.

·       Must address one or more FY18/19 PH/TBIRP CTRR Focus Areas.

Preproposal is required; application submission is by invitation only.

·      Maximum funding of $200,000 for total costs (includes direct and indirect costs).

• ·       Maximum period of performance is 12 months.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PH/TBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBRap.org

The FY18 AIMM Program Announcement and General Application Instructions are posted on Grants.gov.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) Research and Development Directorate (J9) manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

http://cdmrp.army.mil/funding/dmrdp

AIMM Research Award – is due September 19, 2018

Independent investigators at all academic levels (or equivalent)

• Supports highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine
• Supports novel research concepts and development of enabling technologies; not intended to support incremental advances on previous or ongoing work
• Supports applied research efforts that initiate or enhance potential game-changers; clinical trials are not allowed.
• Projects proposed should be relevant to at least one DoD medical research program area.  Cross-cutting research projects with the potential to benefit multiple DoD medical research program areas are highly encouraged. 
• Applications using synthetic or systems biology-based approaches are highly encouraged

• ·        Preliminary data that are relevant to the proposed research are encouraged, but not required.

• Preproposal is required; application submission is by invitation only
• Maximum funding of $350,000 for direct costs (plus indirect costs)
• Maximum period of performance is 18 months

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY18 Defense Appropriation provides $21 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP) to support high-impact research that will identify effective treatments and accelerate their clinical application, identify objective markers for improved definition and diagnosis, and/or provide a better understanding of the pathobiology underlying the complex of Gulf War Illness symptoms. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

http://cdmrp.army.mil/funding/gwirp

New Investigator Award – Letter of Intent due October 18, 2018

• PIs may apply under one of the following three eligibility categories:
• Transitioning Postdoctoral Fellow: Senior postdoctoral fellows who have completed at least 3 years of postdoctoral training.
• Early-Career Investigator: Independent investigators within 5 years since their last training position.
• New GWI Researcher: Established independent investigators who have received less than $300,000 in federally funded, non-mentored GWI research
• Submission of a Letter of Intent is required.
• Encourages applications from early stage and established investigators new to the field of GWI research.
• Previous experience in GWI research is not required; however, collaborations with experienced GWI researchers are encouraged.
• Preliminary data are not required, and if provided, do not necessarily have to come from the GWI research field.
• Studies that provide outcomes clearly translatable to clinical use are encouraged.
• Clinical trials are not allowed.
• The maximum allowable funding for the entire period of performance is $500,000 for direct costs.
• The maximum period of performance is 3 years.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBRap.org

The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Vision Research Program (VRP) to support innovative, high-impact vision research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 VRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Focused Translational Team Science Award (FTTSA) – Preproposal due September 4, 2018

PIs must be independent investigators at or above the level of Associate Professor (or equivalent) with experience in developing and running large-scale initiatives.

• Co-investigators may be independent investigators at all academic levels (or equivalent).
• Preproposal is required; application submission is by invitation only.
• Support highly collaborative and translational team initiatives that would fundamentally advance the understanding and treatment of vision trauma. 
• Proposed research must focus on eye injury or visual dysfunction as related to a traumatic event.  Examples of trauma include, but are not limited to:
• • Blast, blunt, thermal or chemical trauma;
  • Trauma caused by directed energy weapons such as laser, microwaves and particle beams;
  • Ionizing radiation
• Supports a multifaceted, multidisciplinary and highly coherent investigation with 3-5 teams addressing complementary and synergistic questions that center around a specific trauma.  Examples of questions include, but are not limited to:
• • Elucidation of molecular, cellular, and biophysical mechanisms;
  • Identification of biomarkers and potential therapeutic targets;
  • Development and validation of therapeutic agents and/or devices;
  • Development and validation of drug delivery platforms appropriate for said trauma;
  • Development or improvement of clinically relevant models for said trauma;
  • Design of protection to mitigate the impact of said trauma on eye and vision.
  • The proposal should spell out the goals of individual teams as well as describe the ways for the teams to cooperate and effectively share and utilize the newly acquired knowledge in moving the project forward.
• Preliminary data required.
• May include a pilot clinical trial component that collects preliminary data to support the feasibility, rationale and design of subsequent clinical trials.
• Emphasis is on synergy, translational potential, and strategy to transition findings into products.
• Maximum funding of $5.0M for direct costs (plus indirect costs)
• Maximum period of performance is 4 year

Investigator Initiated Research Award (IIRA) – Preproposal due September 4, 2018

• Independent investigators at all academic levels (or equivalent).
• Preproposal is required; application submission is by invitation only.
• Supports studies that will yield highly impactful discoveries or major advancements in the research and/or patient care of the military-relevant vision trauma.
• Must focus on eye injury or visual dysfunction as related to a military-related traumatic event.  Examples of trauma include, but are not limited to:
• • Blast, blunt, thermal or chemical trauma;
  • Trauma caused by directed energy weapons such as laser, microwaves and particle beams;
  • Ionizing radiation
• Preliminary data required.
• Clinical trials are not allowed.
• Maximum funding of $500K for direct costs (plus indirect costs)
• Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the VRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

FY18 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

 

Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:

• ·         Prevent breast cancer (primary prevention)
• ·         Identify determinants of breast cancer initiation, risk, or susceptibility
• ·         Distinguish deadly from non-deadly breast cancers
• ·         Conquer the problems of over diagnosis and overtreatment
• ·         Identify what drives breast cancer growth; determine how to stop it
• ·         Identify why some breast cancers become metastatic
• ·         Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
• ·         Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
• ·         Eliminate the mortality associated with metastatic breast cancer

 

http://cdmrp.army.mil/funding/bcrp

 

Breakthrough Award Level 1 & 2– Letter of Intent due November 1, 2018

• ·         Investigators at all academic levels (or equivalent) are eligible to be names as Principal Investigator (PI).
• ·         Applications from senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged underfunding Level 1 and 2.
• ·         Each investigator may be named on only one Funding Level 1 application and Funding Level 2 application as a PI or Initiating PI.
• ·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
• ·         Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
• ·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
• ·         When submitting the pre-application, it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
• ·         There are no limitations on the number of applications for which an investigator may be named as a
• ·         Partnering PI.  However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.
• ·         Additional funds are available for applications submitted under the Partnering PI Option.
• ·         Clinical trials are not allowed.
• ·         Submission of a Letter of Intent is required prior to full application submission.
• ·         Funding Level 1:
• ·         Maximum funding of $375,000 for direct costs (plus indirect costs)
• ·         Maximum period of performance is 3 years
• ·         Funding Level 1 – Partnering PI Option:
• ·         Maximum funding of $600,000 for direct costs (plus indirect costs)
• ·         Maximum period of performance is 3 years
• ·         Funding Level 2:
• ·         Maximum funding of $750,000 for direct costs (plus indirect costs)
• ·         Maximum period of performance is 3 years
• ·         Funding Level 2 – Partnering PI Option:
• ·         Maximum funding of $1M for direct costs (plus indirect costs)
• ·         Maximum period of performance is 3 years

 

Breakthrough Award Level 3 & 4– Preproposal due September 14, 2018

• ·         Independent investigators at all academic levels (or equivalent) are eligible to be names as PI.
• ·         Each investigator may submit one Funding Level 3 pre-application and on Funding Level 4 pre-application as a PI or Initiating PI.
• ·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
• ·         Potential impact of the research may be near-terms or long-term, but it must be significant and go beyond an incremental advancement.
• ·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
• ·         When submitting the pre-application it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
• ·         Clinical trials are allowed.
• ·         There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.
• ·         Applications must include two or more breast cancer advocates on their research team.
• ·         Submission of a preproposal is required; application submission is by invitation only.
• ·         Funding Level 3:
• ·         Maximum funding of $2.5M in direct costs (plus indirect costs)
• ·         Maximum period of performance is 4 years
• ·         Funding Level 3 – Partnering PI Option:
• ·         Maximum funding of $4M for direct costs (plus indirect costs)
• ·         Maximum period of performance is 4 years
• ·         Funding Level 4 and Funding Level 4 – Partnering PI Option:
• ·         Maximum funding of $10M for direct costs (plus indirect costs)
• ·         Maximum period of performance is 4 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

 

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY18 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health and Traumatic Brain Injury Research Program (PHTBIRP) to support specific Defense Health Agency (DHA) J9 Directorate research program areas, including Joint Program Committee-5/Military Operational Medicine Research Program (JPC-5/MOMRP).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The PH/TBIRP and JPC-5/MOMRP are providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 PHTBIRP Program Announcement and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in August 2018.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

http://cdmrp.army.mil/pubs/press/2018/18phtbipreann_r2oe

Resiliency and Readiness Optimization/ Enhancement (R2OE)Translational Research Award

Intramural (DoD) and extramural investigators at all academic levels (or equivalent) are eligible to submit applications

Proposals/applications to the FY18 PHTBIRP R2OE Translational Research award should support research with the goal of evaluating evidence-based interventions and techniques to optimize and enhance resilience and psychological health readiness of Service members (SM).  The expectation of this research is to demonstrate the utility of these resiliency and readiness enhancement interventions and techniques to benefit our SMs and the public at large.

·      The maximum period of performance is 3 years.

The maximum allowable total costs per award (direct and indirect) for the entire period of performance is $3M

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PHTBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY18 Defense Appropriation provides $21 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP) to support high-impact research that will identify effective treatments and accelerate their clinical application, identify objective markers for improved definition and diagnosis, and/or provide a better understanding of the pathobiology underlying the complex of Gulf War Illness symptoms. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The GWIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY18 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in August 2018. Pre-application and application deadlines will be available when the Program Announcement is released. This pre-announcement should not be construed as an obligation by the government.

http://cdmrp.army.mil/pubs/press/2018/18gwirppreann_nia

The following mechanism is planned for release:

New Investigator Award

• PIs may apply under one of the following three eligibility categories:
• Transitioning Postdoctoral Fellow: Senior postdoctoral fellows who have completed at least 3 years of postdoctoral training.
• Early-Career Investigator: Independent investigators within 5 years since their last training position.
• Submission of a Letter of Intent is required.
• Encourages applications from early stage and established investigators new to the field of GWI research.
• Previous experience in GWI research is not required; however, collaborations with experienced GWI researchers are encouraged.
• Preliminary data are not required, and if provided, do not necessarily have to come from the GWI research field.
• Studies that provide outcomes clearly translatable to clinical use are encouraged.
• Clinical trials are not allowed.
• Submission of a Letter of Intent is required.· New GWI Researcher: Established independent investigators who have received less than $300,000 in federally funded, non-mentored GWI research.
• The maximum allowable funding for the entire period of performance is $500,000 for direct costs.
• The maximum period of performance is 3 years.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY18 Defense Appropriation provides $12 million (M) to the Department of Defense Reconstructive Transplant Research Program (RTRP) to support research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 RTRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Focus Areas:  The FY18 RTRP encourages research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA) in the following focus areas:

• ·        Reduce the risks of VCA-associated immunotherapy
• ·        Revolutionize ex vivo VCA tissue preservation strategies to extend the timeline between procurement and transplantation
• ·        Identify near- and long-term functional, quality-of-life, and psychosocial outcomes in VCA

http://cdmrp.army.mil/funding/rtrp

Concept Award (CA) – Letter of Intent due 10/3/18

Investigators at or above the level of postdoctoral fellow (or equivalent)

• Pre-application (Letter of Intent) is required.
• Supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to reconstructive transplant. 
• Preliminary data are NOT allowed.
• Reviewers at both tiers of review will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organizations.
• Applications must address at least one of the FY18 RTRP Focus Areas.

·      Maximum funding of $200,000 for total costs (direct plus indirect costs)

• ·      Maximum period of performance is 18 months

Investigator-Initiated Research Award (IIRA) – Preproposal due 8/15/18

Independent investigators at all academic levels (or equivalent)

• Preproposal is required; full application submission is by invitation only.
• Supports studies with potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.
• Preliminary or published data required.
• Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.
• Applications must address at least one of the FY18 RTRP Focus Areas.

Individual PIs:

·      Maximum funding of $1 million (M) for total costs

·      Maximum period of performance is 3 years

Multiple PI Option:

·      Maximum funding of $1.5M for total costs

• ·      Maximum period of performance is 3 years

Qualitative Research Award (QRA) – Preproposal due 8/15/18

Independent investigators at all academic levels (or equivalent)

• Preproposal is required; full application submission is by invitation only.
• Supports qualitative research studies that will help researchers and clinicians to better understand the experiences of individuals who are considering, or have already received, reconstructive transplant surgery.
• Demonstrated qualitative research experience within the research team is required.
• Applications must address the following FY18 RTRP Focus Area:

○       Identify near- and long-term functional, quality-of-life, and psychosocial outcomes in VCA

Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.

·      Maximum funding of $1M for total costs

·      Maximum period of performance is 3 years

Multiple PI Option:

·      Maximum funding of $1.5M for total costs

• ·      Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RTRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

NAVREF was recently recognized for our transparency with a 2018 Gold Seal on our GuideStar Nonprofit Profile!

GuideStar is the world’s largest source of information on nonprofit organizations. More than 8 million visitors per year and a network of 200+ partners use GuideStar data to grow support for nonprofits.

In order to get the 2018 Gold Seal, NAVREF shared important information with the public using our profile on www.guidestar.org. Now our community members and potential donors can find in-depth information about our goals, strategies, capabilities, and progress. We’re shining a spotlight on the difference we help make in the world. 

Don't believe us? Check out our profile on GuideStar or look at our logo at the footer of our website.